Next Phase Newsletter

A family office based in the Southern United States is currently seeking new investments in healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in the Southern U.S. but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, healthcare IT, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company headquartered in Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.

The firm is currently looking for innovative therapeutics targeting cardiovascular-metabolic diseases including obesity, heart failure, metabolic abnormality-induced vascular dysfunction, kidney protection, and stroke. The firm also seeks new treatments for the following indications: sensory neuronal system conditions such as retinal and cochlear degeneration; pain relief through Mu-opioid receptor-dependent and non-opioid mechanisms; immune dysfunctions through mechanisms of homeostatic inflammation, APC, inflammatory factor and B cell function; and fibrosis of lung and the digestive system. However the firm is not interested in the triggers of fibrosis such as inflammation or viral infection. In addition, the firm is interested in muscle atrophy, anemia, and rare/serious diseases.

The firm is looking to partner with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A new corporate VC fund formed by a biopharmaceutical company is looking to invest in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is currently open to opportunities worldwide.

The firm is currently looking to invest in three indication areas: oncology, immunology, and hematology. The fund is technology-agnostic, and is therefore interested in therapeutic, medical device, diagnostic and healthcare IT opportunities in these three areas. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective. Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest). While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel network focused on social impact investing with chapters throughout the United States is currently looking for investments in healthcare. The group typically participates in seed and series A raises of $300,000-$1.5 million, but may take part in raises of up to $3 million. In general the group only considers opportunities in the USA and Canada, but the group will also consider global health companies located in the developing world.

The Group is open to opportunities in several industries, including healthcare technologies. The group does not invest in biotech drug development, but is interested in medical technology companies with lower capital requirements and a shorter path to commercialization. The group generally invests in companies that have completed product development and have a product on the market. The group is particularly interested in global health companies that are developing last-mile solutions for delivering healthcare in the developing world. Companies developing a product that is not regulated by the FDA, including consumer health, healthcare IT and lab equipment/lab software companies are more likely to be of interest.

The group typically invests in companies that have revenues, or which can demonstrate user traction among free users eg. via a successful trial or partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharma group based in the US is looking to form partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm is actively pursuing these opportunities and is willing to look globally.

The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases.  The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to both biologic and small molecule opportunities, but is generally not focused on cell therapies such as CAR-T technologies. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com